The Effectiveness of Intravitreal Bevacizumab with or without Triamcinolone Acetonide for Diabetic Macular Edema Treatment
Abstract
Purpose To study effectiveness of Intravitreal Bevacizumab 2.5mg IVB alone or Bevacizumab 1.25mg in combination with 2 mg Triamcinolone Acetonide IVTA in center-involved diabetic macular edema.
Patients and methods: 61 eyes enrolled in this prospective, non-randomized, comparative study ( 36 eyes were injected with IVB, 25 eyes were injected with IVTA + IVB). Evaluation of best-corrected visual acuity BCVA, central macular thickness CMT, and intraocular pressure IOP was conducted at 4,8,12 weeks after treatment.
Results: Significant CMT reduction was observed in each group along the follow-up period (P<0.001). The mean reduction of CMT was more significant in combination IVTA + IVB at 4 weeks (P<0.05). Significant BCVA improvement was observed each group along the follow-up period (P<0.001). BCVA changes between two groups were not significant different at follow-up period (P>0.05). The number of injections was significantly lower in IVTA + IVB group than IVB group (P=0.0045). One patient developed IOP raised more than 21 mmHg, which were treated with anti glaucoma medications.
Conclusion: Bevacizumab 2.5mg Intravitreal injection alone or Bevacizumab 1.25mg in combination with 2 mg Triamcinolone Acetonide had significantly reduced CMT, and this effect was more significant in combination term at short term. Although treatment in both terms had significantly improved BCVA at all follow-up period with no differentiation between the two groups. The combination therapy may reduce the number of injections. Intravitreal injections were not accompanied with significant IOP increas.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
